Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Indivior Pharmaceuticals, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

No material changes in market risk have occurred from the information provided in Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the Company’s Annual Report on Form 10-K. 31